NO20012301L - Ny fremgangsmåte for behandling - Google Patents

Ny fremgangsmåte for behandling

Info

Publication number
NO20012301L
NO20012301L NO20012301A NO20012301A NO20012301L NO 20012301 L NO20012301 L NO 20012301L NO 20012301 A NO20012301 A NO 20012301A NO 20012301 A NO20012301 A NO 20012301A NO 20012301 L NO20012301 L NO 20012301L
Authority
NO
Norway
Prior art keywords
plasma
insulin sensitizer
treatment
methods
diabetes mellitus
Prior art date
Application number
NO20012301A
Other languages
English (en)
Other versions
NO20012301D0 (no
NO328391B1 (no
Inventor
Lisa Benincosa
William Jusko
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20012301(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20012301D0 publication Critical patent/NO20012301D0/no
Publication of NO20012301L publication Critical patent/NO20012301L/no
Publication of NO328391B1 publication Critical patent/NO328391B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Metode for behandling av type 2 diabetes mellitus og lidelser knyttet til diabetes mellitus, hvilken metode omfatter administrering til et menneske eller ikke-humant pattedyr som har behov for dette, av en effektiv, ikke-toksisk mengde av en insulin-sensibilisatorfor å gi en plasma-konsentrasjon av insulin-sensibilisatoren på minst et terskelnivå ("terskel-plasmakonsentrasjonen") innenfor området av effektive plasmanivåer av insulin-sensibilisatoren, preparater for anvendelse ved en slik metode og metoder for bestemmelse av plasmakonsentrasjoner av aktiv bestanddel ved slike metoder.
NO20012301A 1998-11-12 2001-05-10 Farmasoytisk preparat med forlenget frigjoring og anvendelse derav NO328391B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9824893.3A GB9824893D0 (en) 1998-11-12 1998-11-12 Novel method of treatment
PCT/US1999/026746 WO2000027341A2 (en) 1998-11-12 1999-11-12 Novel method of treatment

Publications (3)

Publication Number Publication Date
NO20012301D0 NO20012301D0 (no) 2001-05-10
NO20012301L true NO20012301L (no) 2001-07-09
NO328391B1 NO328391B1 (no) 2010-02-08

Family

ID=10842389

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012301A NO328391B1 (no) 1998-11-12 2001-05-10 Farmasoytisk preparat med forlenget frigjoring og anvendelse derav

Country Status (40)

Country Link
EP (2) EP1759698A1 (no)
JP (1) JP2003521455A (no)
KR (2) KR20010080440A (no)
CN (3) CN1771943A (no)
AP (2) AP2005003432A0 (no)
AR (2) AR029317A1 (no)
AT (1) ATE366573T1 (no)
AU (1) AU768303B2 (no)
BG (2) BG110061A (no)
BR (1) BR9915284A (no)
CA (1) CA2350425C (no)
CO (1) CO5150158A1 (no)
CY (1) CY1106892T1 (no)
CZ (1) CZ299801B6 (no)
DE (1) DE69936533T2 (no)
DK (1) DK1135128T3 (no)
DZ (1) DZ2938A1 (no)
EA (2) EA200700968A1 (no)
ES (1) ES2289833T3 (no)
GB (1) GB9824893D0 (no)
HK (1) HK1041202B (no)
HR (1) HRP20010344B1 (no)
HU (1) HUP0104262A3 (no)
IL (1) IL143088A0 (no)
MA (1) MA26759A1 (no)
MY (1) MY128347A (no)
NO (1) NO328391B1 (no)
NZ (1) NZ527132A (no)
OA (1) OA12193A (no)
PE (1) PE20001239A1 (no)
PL (1) PL349421A1 (no)
PT (1) PT1135128E (no)
RS (1) RS50130B (no)
SK (1) SK286357B6 (no)
TR (1) TR200101348T2 (no)
TW (1) TWI234456B (no)
UA (1) UA79730C2 (no)
UY (2) UY25797A1 (no)
WO (1) WO2000027341A2 (no)
ZA (1) ZA200103793B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
ES2259736T3 (es) * 2001-12-21 2006-10-16 Smithkline Beecham Corporation Regimen de dosificacion para activadores de ppar-gamma-.
WO2012074375A1 (en) * 2010-12-01 2012-06-07 N.V. Nutricia Prevention or treatment of overweight and obesity in type 2 diabetic patients

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
FI904414A7 (fi) * 1988-03-08 1990-09-07 Pfizer Tiatsolidiinidioni-hypoglykeemisesti vaikuttavat aineet
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469331A (ja) * 1990-07-10 1992-03-04 Asahi Chem Ind Co Ltd 徐放性エマルジョン製剤
JP2572673B2 (ja) * 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH06510286A (ja) * 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー ３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478853A (en) * 1992-10-12 1995-12-26 Adir Et Compagnie Thazolidinedione compounds
US5506245A (en) * 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
CA2115587A1 (en) * 1993-02-18 1994-08-19 Hayato Kihara Styrene copolymers, polystyrene compositions, processes for producing styrene copolymers, and injection-molded articles
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
CN1103590C (zh) * 1993-09-15 2003-03-26 三共株式会社 使用噻唑烷二酮防止或延缓非胰岛素依赖性糖尿病(niddm)的发作
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes

Also Published As

Publication number Publication date
CN1354661A (zh) 2002-06-19
HRP20010344A2 (en) 2002-06-30
MY128347A (en) 2007-01-31
TWI234456B (en) 2005-06-21
DE69936533D1 (de) 2007-08-23
CZ20011656A3 (cs) 2002-06-12
MA26759A1 (fr) 2004-12-20
ATE366573T1 (de) 2007-08-15
AR029149A1 (es) 2003-06-18
BR9915284A (pt) 2002-02-13
JP2003521455A (ja) 2003-07-15
SK286357B6 (sk) 2008-08-05
AP1580A (en) 2006-02-24
NZ527132A (en) 2005-01-28
NO20012301D0 (no) 2001-05-10
RS50130B (sr) 2009-03-25
EA200100539A1 (ru) 2001-12-24
HRP20010344B1 (en) 2008-02-29
CA2350425A1 (en) 2000-05-18
OA12193A (en) 2006-05-09
PL349421A1 (en) 2002-07-29
AR029317A1 (es) 2003-06-25
CO5150158A1 (es) 2002-04-29
BG105569A (en) 2002-01-31
DZ2938A1 (fr) 2004-03-15
WO2000027341A3 (en) 2000-09-08
EA009192B1 (ru) 2007-12-28
EP1135128A2 (en) 2001-09-26
PT1135128E (pt) 2007-10-12
EA200700968A1 (ru) 2008-06-30
NO328391B1 (no) 2010-02-08
HK1041202B (en) 2007-10-05
TR200101348T2 (tr) 2002-02-21
UA79730C2 (en) 2007-07-25
EP1135128A4 (en) 2003-07-16
BG65577B1 (bg) 2009-01-30
UY25797A1 (es) 2000-12-29
WO2000027341A2 (en) 2000-05-18
AU1719600A (en) 2000-05-29
HUP0104262A3 (en) 2003-06-30
GB9824893D0 (en) 1999-01-06
HUP0104262A2 (en) 2002-08-28
KR20010080440A (ko) 2001-08-22
KR20070048279A (ko) 2007-05-08
YU37401A (sh) 2005-07-19
CN1771943A (zh) 2006-05-17
CA2350425C (en) 2009-06-02
UY25801A1 (es) 2000-08-21
CN1235586C (zh) 2006-01-11
ES2289833T3 (es) 2008-02-01
CZ299801B6 (cs) 2008-11-26
DK1135128T3 (da) 2007-11-05
BG110061A (bg) 2008-12-30
CY1106892T1 (el) 2012-01-25
PE20001239A1 (es) 2000-12-24
CN101244062A (zh) 2008-08-20
EP1135128B1 (en) 2007-07-11
IL143088A0 (en) 2002-11-10
SK6422001A3 (en) 2001-12-03
HK1041202A1 (en) 2002-07-05
AU768303B2 (en) 2003-12-04
AP2005003432A0 (en) 2005-12-31
DE69936533T2 (de) 2008-03-13
ZA200103793B (en) 2002-06-05
EP1759698A1 (en) 2007-03-07

Similar Documents

Publication Publication Date Title
Cartledge et al. Advanced glycation end‐products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes
Palzur et al. Neuroprotective effect of hyperbaric oxygen therapy in brain injury is mediated by preservation of mitochondrial membrane properties
Berchtold et al. Hippocampal brain‐derived neurotrophic factor gene regulation by exercise and the medial septum
Naik et al. Role of oxidative stress in pathophysiology of peripheral neuropathy and modulation by N‐acetyl‐l‐cysteine in rats
AR043188A1 (es) Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias
Jackson et al. Vitamin E and the oxidative stress of exercise
NO20062003L (no) Fremgangsmate og forbindelser for behandling av immunoinflammatoriske forstyrrelser
NO976063L (no) Fremgangsmåte for behandling av diabetes
Kompa et al. Effect of different irrigating solutions on aqueous humour pH changes, intraocular pressure and histological findings after induced alkali burns
Colonna et al. Calcitonin gene-related peptide promotes cerebrovascular dilation during cortical spreading depression in rabbits
ID30237A (id) KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES
AR057631A1 (es) Composiciones y metodos para incrementar la sensibilidad a insulina
Baydas et al. Comparison of the impact of melatonin on chronic ethanol‐induced learning and memory impairment between young and aged rats
WO2004097429A3 (en) Apociii and the treatmentand diagnosis of diabetes
DK1572230T3 (da) Placenta alkalisk phosphatase til at kontrollere diabetes
BR0311161A (pt) Método de tratamento de diabetes
NO20015932L (no) Fremgangsmåte til å behandle diabetes
NO20083276L (no) Behandling av diabetes med tiazolidindion og sulfonylurea
Kuhn et al. Sex, steroids, and stimulant sensitivity
Grover et al. Functional impairment of renal organic cation transport in experimental diabetes
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
Lu et al. Analysis of the mechanism by which melatonin inhibits human eosinophil peroxidase
NO984974L (no) Middel som forbedrer pulmonar sirkulasjon
Kuwabara et al. Pharmacologic intervention in axonal excitability: in vivo assessment of nodal persistent sodium currents in human neuropathies
Nakaizumi et al. The electrotonic architecture of the retinal microvasculature: diabetes-induced alteration

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees